iSAM Funds UK Ltd Has $1.09 Million Stock Position in Edwards Lifesciences Corporation $EW

iSAM Funds UK Ltd lifted its position in Edwards Lifesciences Corporation (NYSE:EW) by 120.9% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 12,100 shares of the medical research company’s stock after buying an additional 6,623 shares during the quarter. Edwards Lifesciences makes up about 0.8% of iSAM Funds UK Ltd’s holdings, making the stock its 28th largest holding. iSAM Funds UK Ltd’s holdings in Edwards Lifesciences were worth $1,095,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. BlackRock Inc. acquired a new position in Edwards Lifesciences in the 2nd quarter worth approximately $5,318,092,000. State Street Corp raised its stake in Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock valued at $2,215,777,000 after purchasing an additional 371,892 shares during the period. Wellington Management Group LLP raised its stake in Edwards Lifesciences by 4.8% during the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after purchasing an additional 989,533 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at $1,274,082,000. Finally, Norges Bank purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $803,686,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.1%

Shares of NYSE:EW opened at $90.80 on Thursday. The firm has a fifty day moving average of $89.74 and a two-hundred day moving average of $85.36. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The firm has a market capitalization of $52.28 billion, a P/E ratio of 52.18, a price-to-earnings-growth ratio of 2.38 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the prior year, the business posted $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the topic of a number of research analyst reports. UBS Group began coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They set a “buy” rating and a $110.00 price target on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Royal Bank Of Canada raised their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their target price for the company from $87.00 to $101.00 in a report on Friday, July 24th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president directly owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This represents a 3.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,045 shares of company stock worth $457,749 over the last 90 days. 0.31% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.